These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3814514)

  • 1. Mycosis fungoides--response to therapy and survival patterns in 85 cases.
    Slevin NJ; Blair V; Todd ID
    Br J Dermatol; 1987 Jan; 116(1):47-53. PubMed ID: 3814514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides.
    Kim YH; Chow S; Varghese A; Hoppe RT
    Arch Dermatol; 1999 Jan; 135(1):26-32. PubMed ID: 9923777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.
    Kim YH; Jensen RA; Watanabe GL; Varghese A; Hoppe RT
    Arch Dermatol; 1996 Nov; 132(11):1309-13. PubMed ID: 8915308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients.
    van Doorn R; Van Haselen CW; van Voorst Vader PC; Geerts ML; Heule F; de Rie M; Steijlen PM; Dekker SK; van Vloten WA; Willemze R
    Arch Dermatol; 2000 Apr; 136(4):504-10. PubMed ID: 10768649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides.
    Wilson LD; Jones GW; Kim D; Rosenthal D; Christensen IR; Edelson RL; Heald PW; Kacinski BM
    J Am Acad Dermatol; 2000 Jul; 43(1 Pt 1):54-60. PubMed ID: 10863224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides.
    de Coninck EC; Kim YH; Varghese A; Hoppe RT
    J Clin Oncol; 2001 Feb; 19(3):779-84. PubMed ID: 11157031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter: Diagnosis and treatment of mycosis fungoides.
    Constantine VS; Fuks ZY
    Arch Dermatol; 1974 Aug; 110(2):301-2. PubMed ID: 4852753
    [No Abstract]   [Full Text] [Related]  

  • 8. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
    Sausville EA; Eddy JL; Makuch RW; Fischmann AB; Schechter GP; Matthews M; Glatstein E; Ihde DC; Kaye F; Veach SR
    Ann Intern Med; 1988 Sep; 109(5):372-82. PubMed ID: 3408055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case-control study of clinicopathologic features, prognosis, and therapeutic responses in patients with granulomatous mycosis fungoides.
    Li JY; Pulitzer MP; Myskowski PL; Dusza SW; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2013 Sep; 69(3):366-74. PubMed ID: 23685027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
    Kim YH; Bishop K; Varghese A; Hoppe RT
    Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total skin electron beam therapy in mycosis fungoides. Our experience from 1985 to 1999.
    Rampino M; Ragona R; Monetti U; Mussano A; Guarneri A; Sannazzari GL
    Radiol Med; 2002; 103(1-2):108-14. PubMed ID: 11859306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical course and treatment of mycosis fungoides].
    Laczkowska M
    Pol Tyg Lek; 1988 Feb; 43(5):131-5. PubMed ID: 3405881
    [No Abstract]   [Full Text] [Related]  

  • 13. Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival.
    Russell-Jones R; Child F; Olavarria E; Whittaker S; Spittle M; Apperley J
    Ann N Y Acad Sci; 2001 Sep; 941():147-54. PubMed ID: 11594568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides.
    van Santen S; Roach RE; van Doorn R; Horváth B; Bruijn MS; Sanders CJ; de Pooter JC; van Rossum MM; de Haas ER; Veraart JC; Bekkenk MW; Vermeer MH; Willemze R
    JAMA Dermatol; 2016 Sep; 152(9):992-1000. PubMed ID: 27276223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapidly progressing mycosis fungoides presenting as follicular mucinosis.
    Bonta MD; Tannous ZS; Demierre MF; Gonzalez E; Harris NL; Duncan LM
    J Am Acad Dermatol; 2000 Oct; 43(4):635-40. PubMed ID: 11004619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythrocyte sedimentation rate as an independent prognostic factor in mycosis fungoides.
    Hallermann C; Niermann C; Fischer RJ; Schulze HJ
    Br J Dermatol; 2012 Apr; 166(4):873-4. PubMed ID: 22059808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
    Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
    Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
    Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome).
    Jones GW; Rosenthal D; Wilson LD
    Cancer; 1999 May; 85(9):1985-95. PubMed ID: 10223240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total skin electron irradiation for mycosis fungoides: failure analysis and prognostic factors.
    Tadros AA; Tepperman BS; Hryniuk WM; Peters VG; Rosenthal D; Roberts JT; Figueredo AT
    Int J Radiat Oncol Biol Phys; 1983 Sep; 9(9):1279-87. PubMed ID: 6885540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.